课题基金 / 基金详情

TREATMENT OF TB WITH MICROENCAPSULATED DRUGS

TREATMENT OF TB WITH MICROENCAPSULATED DRUGS
用微胶囊药物治疗结核病
批准号：
2457826
负责人：
William W Barrow
金额：
$46.12万
依托单位：
SOUTHERN RESEARCH INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
1995
资助国家：
美国
项目状态：
已结题
起止时间：
1995-08-01 至 1999-07-31
来源：
https://reporter.nih.gov/project-details/2457826
关键词：
antitubercular agents drug design /synthesis /production drug screening /evaluation ethambutol isoniazid laboratory mouse lymphocyte proliferation microcapsule phagocytosis rifamycins streptomycin tissue /cell culture

项目摘要

项目成果

William W Barrow的其他基金

相关文献

中文摘要
翻译
描述：(改编自申请人摘要)。结核病是一个重要的 年在全球范围内感染，其在美国的发病率正在上升。 有鉴于此，人们对…的发展很感兴趣 有效对抗感染的新型药物或给药系统 以提高患者的存活率。这个应用程序处理开发 微囊化抗结核药物的研究，希望实现 前述目标。一旦开发出来，这些药物将在 体外，使用小鼠巨噬细胞系和人类单核细胞 排队。之后，这些药物将在感染结核杆菌的小鼠身上进行测试。
英文摘要
DESCRIPTION: (Adapted from Applicant's Abstract). TB is an important infection worldwide and its incidence is increasing in the U. S. In view of this, much interest has been directed to the development of novel drugs or delivery systems that are effective against the infection to improve patient survival. This application deals with the development of microencapsulated anti-TB drugs with the hope of accomplishing the aforementioned goal. Once developed, these drugs will be tested in vitro, using a murine macrophage cell line and a human monocytic cell line. Afterwards, the drugs will be tested in mice infected with MTB.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Broad-spectrum Antifolates for Treatment of Drug Resistant Bacillus anthracis
Broad-spectrum Antifolates for Treatment of Drug Resistant Bacillus anthracis
Broad-spectrum Antifolates for Treatment of Drug Resistant Bacillus anthracis
Broad-spectrum Antifolates for Treatment of Drug Resistant Bacillus anthracis